Cadrenal Therapeutics, Inc. Common Stock
CVKDAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 11, 2024 | H.C. Wainwright | Joseph Pantginis | $32.00(+114%) | $14.93 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Apr 7, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 16, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 11, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 14, 2024 |
Earnings History
Next report: Mar 17, 2027 · EPS est. $-0.86| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-1.14 | $-1.42 | — | — |
| May 7, 2026 | $-1.04 | $-1.51 | — | — |
| Mar 31, 2026 | $-1.41 | $-1.17 | — | — |
| Nov 10, 2025 | $-1.31 | $-1.55 | — | — |
| Aug 11, 2025 | $-1.87 | $-1.60 | — | — |
| May 8, 2025 | $-2.09 | $-1.64 | — | — |
| Mar 13, 2025 | $-2.74 | $-1.71 | $2.1K | — |
| Nov 7, 2024 | $-2.18 | $-1.83 | — | — |
News
PONTE VEDRA, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) (“Cadrenal” or the “Company”), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced that its Board of Directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the Company and its asset portfolio.
PONTE VEDRA, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced that CEO Quang X. Pham will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.
PONTE VEDRA, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced that CEO Quang X.
FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study CAD-1005 Targets a Significant Unmet Need, with Approximately 50,000 Confirmed Acute HIT Diagnoses Annually in the U.S. and an Estimated $2 Billion in Peak Annual Revenue Opportunity PONTE VEDRA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, …
Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shielding Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shielding